View Older Stories View More Recent Stories

Oct 22, 2024 08:02AM Monopar Therapeutics (MNPR) Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024
Oct 22, 2024 08:00AM Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024
Oct 15, 2024 08:00AM Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers
Oct 7, 2024 08:00AM Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers
Sep 12, 2024 08:00AM Monopar Therapeutics (MNPR) Reports Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
Sep 12, 2024 08:00AM Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
Sep 4, 2024 08:00AM Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Aug 27, 2024 04:06PM Monopar Therapeutics (MNPR) Regains Compliance with Nasdaq Minimum Bid Price Rule
Aug 27, 2024 04:05PM Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule
Aug 21, 2024 08:00AM Monopar Therapeutics (MNPR) Cleared to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers
Aug 21, 2024 08:00AM Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers
Aug 14, 2024 08:00AM Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr
Aug 9, 2024 08:01AM Monopar Therapeutics (MNPR) Announces 1-for-5 Reverse Stock Split
Aug 9, 2024 08:00AM Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments
Aug 9, 2024 08:00AM Monopar Therapeutics Announces 1-for-5 Reverse Stock Split
Jul 9, 2024 07:00AM Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr
Jun 25, 2024 08:00AM Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24
Jun 11, 2024 07:31AM Monopar (MNPR) and NorthStar Amend & Extend Collaboration
Jun 11, 2024 07:30AM Monopar and NorthStar Amend & Extend Collaboration
Jun 11, 2024 07:30AM Monopar and NorthStar Amend & Extend Collaboration
Jun 10, 2024 08:00AM Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting
May 24, 2024 08:00AM Monopar Therapeutics (MNPR) Announces CFO Succession
May 24, 2024 08:00AM Monopar Announces CFO Succession
May 9, 2024 07:00AM Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline
Apr 18, 2024 08:00AM Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
Apr 16, 2024 08:13AM Monopar Therapeutics (MNPR) Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
Apr 16, 2024 08:00AM Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
Apr 10, 2024 08:03AM Monopar Therapeutics (MNPR) Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
Apr 10, 2024 08:00AM Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
Mar 28, 2024 07:00AM Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
Mar 5, 2024 07:00AM Monopar Therapeutics (MNPR) Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
Mar 5, 2024 07:00AM Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
Feb 27, 2024 07:00AM Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
Feb 22, 2024 07:01AM Monopar Therapeutics (MNPR) Reports Preclinical Data for MNPR-101
Feb 22, 2024 07:00AM Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers
Feb 20, 2024 08:00AM Monopar Therapeutics (MNPR) Cleared to Proceed with First-in-Human Phase 1 Trial of MNPR-101-Zr
Feb 20, 2024 08:00AM Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
Nov 1, 2023 07:02AM Monopar Therapeutics (MNPR) Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b
Nov 1, 2023 07:00AM Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
Oct 10, 2023 07:00AM Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference
Sep 5, 2023 07:00AM Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Aug 8, 2023 07:00AM Monopar Provides Encouraging Camsirubicin Clinical Data Update
Jul 11, 2023 07:02AM Monopar Therapeutics (MNPR) Announces MNPR-101 Radiopharma Collaboration Agreement with CSI Singapore
Jul 11, 2023 07:00AM Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore
Jun 21, 2023 07:00AM Monopar to Participate in the Radiopharma Forum by the Lake 2023
Jun 14, 2023 07:00AM Monopar to Participate in the Maxim Group’s Healthcare Virtual Conference
Jun 1, 2023 07:00AM Monopar Therapeutics (MNPR) Reports Encouraging Camsirubicin Phase 1b Trial Update
Jun 1, 2023 07:00AM Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update
Mar 28, 2023 07:00AM Monopar to Present at the Jefferies Radiopharma Innovation Summit
Mar 28, 2023 07:00AM Monopar to Present at the Jefferies Radiopharma Innovation Summit
View More Recent Stories View Older Stories